ArticleFrontiers in medicine2025
Human epidermis models demonstrate mediator role of TLR2 and TLR3 for psoriatic inflammation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is a multifactorial systemic autoinflammatory disease that is characterized by complex signaling between keratinocytes and immune cells. The trigger factors for the cutaneous manifestation of the disease are divers but have in common that they induce an activation of the Toll-like receptor (TLR) signaling pathways. This is best described for the activation of TLR7/8/9 in dendritic cells. In this study, we investigated the role of TLR2 and TLR3 activation in keratinocytes for the expression of psoriatic hallmarks in the skin. We set up 3D epidermis models using wild type keratinocytes and TLR2 knockout and TLR3 knockout (KO) keratinocytes derived from the wild type keratinocytes and treated them with TLR agonists. Immunohistochemical, western blot, and multiplex analysis showed that the TLR activation induced the expression of psoriasis associated markers like S100A7, p-STAT3, CXCL-1, IL-8, IL-1α, S100A9, and IL-23 in the wild type but not in the TLR KO epidermis models. Thus, TLR2 and TLR3 activation in keratinocytes individually contributes significantly to inducing the release of cytokines and other immune modulators characteristic for a psoriasis like inflammation in 3D epidermis models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.